Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 10 records in total 11
    records per page

    Abnormal Upregulation of Cardiovascular Disease MESHD Biomarker PLA2G7 Induced by Proinflammatory Macrophages in COVID-19 patients

    Authors: Yang LI; Yongzhong JIANG; Yi ZHANG; Naizhe LI; Qiangling YIN; Linlin LIU; Xin LV; Yan LIU; Aqian LI; Bin FANG; Jiajia LI; Hengping YE; Gang YANG; Xiaoxian CUI; Yang LIU; Yuanyuan QU; Chuan LI; Jiandong LI; Dexin LI; Shiwen WANG; Zhongtao GAI; Faxian ZHAN; Mifang LIANG; Scott Hensley

    doi:10.1101/2020.08.16.20175505 Date: 2020-08-18 Source: medRxiv

    BACKGROUND. Coronavirus disease MESHD 2019 (COVID-19) triggers distinct patterns of pneumonia HP pneumonia MESHD progression with multiorgan disease, calling for cell- and/or tissue-type specific host injury markers. METHODS. An integrated hypothesis-free single biomarker analysis framework was performed on nasal swabs (n=484) from patients with COVID-19 in GSE152075. The origin of candidate biomarker was assessed in single-cell RNA data (GSE145926). The candidate biomarker was validated in a cross-sectional cohort (n=564) at both nucletide and protein levels. RESULTS. Phospholipase A2 group VII (PLA2G7) was identified as a candidate biomarker in COVID-19. PLA2G7 was predominantly expressed by proinflammatory macrophages in lungs emerging with progression of COVID-19. In the validation stage, PLA2G7 was found in patients with COVID-19 and pneumonia HP pneumonia MESHD, especially in severe pneumonia HP pneumonia MESHD, rather than patients suffered mild H1N1 influenza infection MESHD. The positive rates of PLA2G7 ranging from 29.37% to 100.00% were positively correlated with not only viral loads in patients with COVID-19 but also severity of pneumonia HP pneumonia MESHD in non COVID-19 patients. Although Ct values of PLA2G7 in severe pneumonia HP pneumonia MESHD was siginificantly lower than that in moderate pneumonia HP pneumonia MESHD (P=7.2e-11), no differences were observed in moderate pneumonia HP pneumonia MESHD with COVID-19 between severe pneumonia HP pneumonia MESHD without COVID-19 (P=0.81). Serum SERO protein levels of PLA2G7, also known as lipoprotein-associated phospholipase A2 (Lp-PLA2), were further found to be elevated and beyond the upper limit of normal in patients with COVID-19, especially among the re-positive patients. CONCLUSIONS. We firstly identified and validated PLA2G7, a biomarker for cardiovascular diseases MESHD ( CVDs MESHD), was abnormally enhanced in COVID-19 patients at both nucletide and protein aspects. These findings provided indications into the prevalence SERO of cardiovascular involvements seen in COVID-19 patients. PLA2G7 could be a hallmark of COVID-19 for monitoring disease progress and therapeutic response.

    The Lebanese Cohort for COVID-19; A Challenge for the ABO Blood SERO Group System

    Authors: Athar Khalil; Mahmoud Hassoun; Rita Feghali

    doi:10.1101/2020.08.02.20166785 Date: 2020-08-04 Source: medRxiv

    A sudden outbreak of pneumonia HP pneumonia MESHD caused by the Severe Acute Respiratory Syndrome Coronavirus 2 MESHD (SARS-CoV-2) has rapidly spread all over the world facilitating the declaration of the resultant disease as a pandemic in March,2020. In Lebanon, the fast action of announcing a state of emergency with strict measures was among the factors that helped in achieving a successful containment of the disease in the country. Predisposing factors for acquiring COVID-19 and for developing a severe form of this disease were postulated to be related to epidemiological and clinical characteristics as well as the genomics signature of a given population or its environment. Biological markers such as the ABO blood SERO group system was amongst those factors that were proposed to be linked to the variability in the disease course and/or the prevalence SERO of this infection among different groups. We therefore conducted the first retrospective case-control study in the Middle-East and North Africa that tackles the association between the blood SERO group types and the susceptibility as well as the severity of SARS-CoV2 infection MESHD. Opposing to the current acknowledged hypothesis, our results have challenged the association significance of this system with COVID-19. Herein, we highlighted the importance of studying larger cohorts using more rigorous approaches to diminish the potential confounding effect of some underlying comorbidities and genetic variants that are known to be associated with the ABO blood SERO group system.

    Pericarditis HP Pericarditis MESHD and myocarditis HP myocarditis MESHD long after SARS-CoV-2 infection MESHD: a cross-sectional descriptive study in health-care workers

    Authors: Rocio Eiros; Manuel Barreiro-Perez; Ana Martin-Garcia; Julia Almeida; Eduardo Villacorta; Alba Perez-Pons; Soraya Merchan; Alba Torres-Valle; Clara Sanchez-Pablo; David Gonzalez-Calle; Oihane Perez-Escurza; Ines Toranzo; Elena Diaz-Pelaez; Blanca Fuentes-Herrero; Laura Macias-Alvarez; Guillermo Oliva-Ariza; Quentin Lecrevisse; Rafael Fluxa; Jose L Bravo-Grandez; Alberto Orfao; Pedro L Sanchez

    doi:10.1101/2020.07.12.20151316 Date: 2020-07-14 Source: medRxiv

    Background: Cardiac sequelae of past SARS-CoV-2 infection MESHD are still poorly documented. We conducted a cross-sectional study in health-care workers to report evidence of pericarditis HP pericarditis MESHD and myocarditis HP myocarditis MESHD after SARS-CoV-2 infection MESHD. Methods We studied 139 health-care workers with confirmed past SARS-CoV-2 infection MESHD (103 diagnosed by RT-PCR and 36 by serology). Participants underwent clinical assessment, electrocardiography, laboratory tests including immune cell profiling and cardiac magnetic resonance (CMR) imaging. Pericarditis HP Pericarditis MESHD was diagnosed when classical criteria were present, and the diagnosis of myocarditis HP myocarditis MESHD was based on the updated CMR Lake-Louise-Criteria. Results: Median age TRANS was 52 years (IQR 41-57), 100 (72%) were women, and 23 (16%) were previously hospitalized for Covid-19 pneumonia HP pneumonia MESHD. At examination (10.4 [9.3-11.0] weeks after infection-like symptoms), all participants presented hemodynamic stability. Chest pain HP Chest pain MESHD, dyspnoea MESHD or palpitations HP were observed in 58 (42%) participants; electrocardiographic abnormalities in 69 (50%); NT-pro-BNP was elevated in 11 (8%); troponin in 1 (1%); and CMR abnormalities MESHD in 104 (75%). Isolated pericarditis HP pericarditis MESHD was diagnosed in 4 (3%) participants, myopericarditis in 15 (11%) and isolated myocarditis HP myocarditis MESHD in 36 (26%). Participants diagnosed by RT-PCR were more likely to still present symptoms than participants diagnosed by serology (73 [71%] vs 18 [50%]; p=0.027); nonetheless, the prevalence SERO of pericarditis HP pericarditis MESHD or myocarditis HP myocarditis MESHD was high in both groups (44 [43%] vs 11 [31%]; p=0.238). Most participants (101 [73%]) showed altered immune cell counts in blood SERO, particularly decreased eosinophil (37 [27%]; p<0.001) and increased CD4-CD8-/loT alpha beta-cell numbers (24 [17%]; p<0.001). Pericarditis HP Pericarditis MESHD was associated with elevated CD4-CD8-/loT alpha beta-cell numbers (p=0.011), while participants diagnosed with myopericarditis or myocarditis MESHD myocarditis HP had lower (p<0.05) plasmacytoid dendritic cell, NK-cell and plasma SERO cell counts and lower anti-SARS-CoV-2- IgG antibody SERO levels (p=0.027). Conclusions: Pericarditis HP Pericarditis MESHD and myocarditis HP myocarditis MESHD with clinical stability are frequent long after SARS-CoV-2 infection MESHD, even in presently asymptomatic TRANS subjects. These observations will probably apply to the general population infected and may indicate that cardiac sequelae might occur late in association with an altered (delayed) innate and adaptative immune response.

    Age TRANS is not the only risk factor in COVID-19: the role of comorbidities and of long staying in residential care homes.

    Authors: Michela D'Ascanio; Marta Innammorato; Lara Pasquariello; Dario Pizzirusso; Giulio Guerrieri; Silvia Castelli; Aldo Pezzuto; Claudia De Vitis; Rita Mancini; Alberto Ricci; Salvatore Sciacchitano

    doi:10.21203/ Date: 2020-07-14 Source: ResearchSquare

    Background: The actual SARS-CoV-2 outbreak caused a highly transmissible disease with a tremendous impact on elderly TRANS people. So far, few studies focused on very elderly TRANS patients (over 80 years old). In this study we examined the clinical presentation and the evolution of the disease in this group of patients, admitted to our Hospital in RomeMethods: This is a single-center, retrospective study performed in the Sant’Andrea University Hospital of Rome. We included patients older than 65 years of age TRANS with a diagnosis of COVID-19, from March 2020 to may 2020, divided in two groups according to their age TRANS (G1 65-80 years old; G2 >80 years old). Data extracted from the each patient record included age TRANS, sex, comorbidities, symptoms at onset TRANS, the Pneumonia HP Severity Index (PSI), the ratio of the partial pressure of oxygen in arterial blood SERO (PaO2) to the inspired oxygen fraction (FiO2) (P/F) on admission, laboratory tests, radiological findings on computer tomography (CT), length of hospital stay (LOS), mortality rate and the viral shedding. The differences between the two groups were analyzed by the Fisher’s exact test or the Wilcoxon signed-rank test for categorical variables and the Mann-Whitney U test for continuous variables. The survival time was estimated by Kaplan-Meier method and Log Rank Test. Univariable Cox proportional hazard regression and ordinal logistic regression were performed to estimate associations between age TRANS, comorbidities and provenance from residential care homes and clinical outcomes.Results: We found that G2 patients had an increased mortaliy rate, also due to (the frequent prevalence SERO of) multiple comorbidities. Moreover we found that patients coming from long-stay residential care homes appeared to be highly susceptible and vulnerable to develop severe manifestations of the disease.Conclusion: We demonstrate that there were considerable differences between Elderly TRANS and Very Elderly TRANS patients in terms of inflammatory activity, severity of disease, adverse clinical outcomes; moreover, to establish a correct risk stratification, comorbidities and information about provenience from residential care homes should be considered.

    Acute Cardiac Injury MESHD and COVID-19 – A Systematic Review and Meta-analysis

    Authors: Husam M Salah; Angel Lopez Candales

    doi:10.21203/ Date: 2020-06-24 Source: ResearchSquare

    Introduction:The ongoing global pandemic, coronavirus disease MESHD 2019 (COVID-19), an illness caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) has ranged from an asymptomatic TRANS state to unprecedented number of deaths worldwide. In symptomatic patients, a viral pneumonia HP pneumonia MESHD can unrelentingly progress to multi-system failure with preferential cardiac tropism MESHD. Although the full spectrum of COVID-19 cardiac manifestations is still not clear; acute cardiac injury MESHD (ACI) remains a common finding. The goal of our study, not only is to examine the current prevalence SERO of ACI among COVID-19 infected MESHD patients but also, the reported mortality.Method:After thoroughly searching the literature for appropriate studies, a systematic review and meta-analysis were performed. Inclusion criteria were 1) Cohort study, case-control study, or case series study. 2) The study population included individuals with COVID-19 3) The presence or absence of cardiac injury MESHD was reported in the study 4) Mortality among patients with cardiac injury MESHD is reported or can be calculated.Results:Ten studies were included with a total of 1664 patients. The prevalence SERO of ACI was 30.8%. The mortality rate among patients with concurrent COVID-19 and ACI was 53%.Conclusion:ACI can occur in one third of patients with COVID-19. Concurrent COVID-19 and ACI entails a high mortality rate. Serum SERO troponin level can be a good prognostic tool in COVID-19.

    Identifying novel factors associated with COVID-19 transmission TRANS and fatality using the machine learning approach

    Authors: Mengyuan Li; Zhilan Zhang; Wenxiu Cao; Yijing Liu; Beibei Du; Canping Chen; Qian Liu; Md. Nazim Uddin; Shanmei Jiang; Cai Chen; Yue Zhang; Xiaosheng Wang

    doi:10.1101/2020.06.10.20127472 Date: 2020-06-12 Source: medRxiv

    The COVID-19 virus has infected millions of people and resulted in hundreds of thousands of deaths worldwide. By using the logistic regression model, we identified novel critical factors associated with COVID19 cases, death MESHD, and case fatality rates in 154 countries and in the 50 U.S. states. Among numerous factors associated with COVID-19 risk, we found that the unitary state system was counter-intuitively positively associated with increased COVID-19 cases and deaths. Blood SERO type B was a protective factor for COVID-19 risk, while blood SERO type A was a risk factor. The prevalence SERO of HIV, influenza and pneumonia HP pneumonia MESHD, and chronic lower respiratory diseases MESHD was associated with reduced COVID-19 risk. Obesity HP Obesity MESHD and the condition of unimproved water sources were associated with increased COVID-19 risk. Other factors included temperature, humidity, social distancing, smoking, and vitamin D intake. Our comprehensive identification of the factors affecting COVID-19 transmission TRANS and fatality may provide new insights into the COVID-19 pandemic and advise effective strategies for preventing and migrating COVID-19 spread.

    Laboratory findings in coronavirus disease MESHD 2019 (COVID-19) patients: a comprehensive systematic review and meta-analysis

    Authors: Mohammad Karimian; Amirreza Jamshidbeigi; Gholamreza Badfar; Milad Azami

    doi:10.1101/2020.06.07.20124602 Date: 2020-06-08 Source: medRxiv

    Background: In early December 2019, the first patient with COVID-19 pneumonia HP pneumonia MESHD was found in Wuhan, Hubei Province, China. Recent studies have suggested the role of primary laboratory tests in addition to clinical symptoms for suspected patients, which play a significant role in the diagnosis of COVID-19. Therefore, the present study was conducted to evaluate laboratory findings in COVID-19 patients. Material and methods: The present meta-analysis was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. This protocol is registered with the code CRD42019145410 in PROSPERO International Database. Results: Finally, 52 studies involving 5490 patients with COVID-19 entered the meta-analysis process. The prevalence SERO of leukopenia HP leukopenia MESHD, lymphopenia HP lymphopenia MESHD, elevated c-reactive protein (CRP), elevated erythrocyte sedimentation rate HP (ESR), elevated serum SERO amyloid A, elevated ferritin was estimated to be 20.9% (95%CI: 17.9-24.3), 51.6% (95%CI: 44.0-59.1), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 74.7% (95%CI: 50.0-89.7), and 72.6% (95%CI: 58.1-83.5), respectively. The prevalence SERO of elevated interleukin-6 was 59.9% (95%CI: 48.2-70.5), CD3 was 68.3% (95%CI: 50.1-82.2), reduced CD4 was 62.0% (95%CI: 51.1-71.6), reduced CD8 was 42.7% (95%CI: 32.2-53.9). The prevalence SERO of elevated troponin-I was 20.6% (95%CI: 9.0-40.5), elevated creatine kinase-MB (CKMB) was 14.7% (95%CI: 7.1-28.0), elevated brain natriuretic peptide (BNP) was 48.9% (95%CI: 30.4-67.7), elevated blood SERO urea nitrogen was 13.1% (95%CI: 6.6-24.4),, elevated creatinine was 7.2% (95%CI: 4.4-11.8), elevated lactate dehydrogenase (LDH) was 53.1% (95%CI: 43.6-62.4), hyperglycemia HP hyperglycemia MESHD was 41.1% (95% CI: 28.2-55.5), elevated total bilirubin was 48.9% (95%CI: 30.4-67.7), reduced albumin was 54.7% (95%CI: 38.1-70.2), reduced pre-albumin was 49.0% (95%CI: 26.6-71.8), and reduced PT was 53.1% (95% CI: 43.6-62.4), and D-dimer was 44.9% (95%CI: 31.0-59.6). Conclusion This study provides a comprehensive description of laboratory characteristics in patients with COVID-19. The results show that lymphopenia HP lymphopenia MESHD, elevated CRP, elevated ESR, elevated ferritin, elevated serum SERO amyloid A, elevated BNP, reduced albumin, reduced pre-albumin, reduced CD3, reduced CD4, reduced CD8, elevated D-dimer, reduced PT, elevated interleukin-2, elevated interleukin-6, elevated LDH and hyperglycemia HP hyperglycemia MESHD are the common findings at the time of admission.

    Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France.

    Authors: Sophie EDOUARD; Philippe COLSON; Clea melenotte; Fabrizio De Pinto; Laurence THOMAS; Bernard LA SCOLA; Matthieu MILLION; Herve TISSOT DUPONT; Philippe GAUTRET; Andreas STEIN; Philippe BROUQUI; Philippe PAROLA; Jean-Christophe LAGIER; Didier RAOULT; Michel Drancourt

    doi:10.1101/2020.05.05.20092064 Date: 2020-05-12 Source: medRxiv

    An indirect immunofluorescent assay was developed in order to assess the serological status of 888 RT-PCR-confirmed COVID-19 patients (1,302 serum samples SERO) and controls in Marseille, France. Incorporating an inactivated clinical SARS CoV-2 isolate as the antigen, the specificity of the assay was measured as 100% for IgA titre [≥] 1:200; 98.6% for IgM titre [≥] 1:200; and 96.3% for IgG titre [≥] 1:100 after testing a series of negative controls as well as 150 serums SERO collected from patients with non-SARS-CoV-2 Coronavirus infection MESHD, non-Coronavirus pneumonia HP pneumonia MESHD and infections known to elicit false-positive serology. Seroprevalence SERO was then measured at 3% before a five-day evolution up to 47% after more than 15 days of evolution. We observed that the seroprevalence SERO as well as the titre of specific antibodies SERO were both significantly higher in patients with a poor clinical outcome than in patients with a favourable evolution. These data, which have to be integrated into the ongoing understanding of the immunological phase of the infection MESHD, suggest that serotherapy may not be a therapeutic option in patients with severe COVID-19 infection MESHD. The IFA assay reported here is useful for monitoring SARS-CoV-2 exposure at the individual and population levels.

    Clinical Characteristics and Short-Term Outcomes of Severe Patients with COVID-19 in Wuhan, China

    Authors: Xiaobo Feng Sr.; Peiyun Li; Liang Ma; Hang Liang; Jie Lei; Wenqiang Li; Kun Wang; Yu Song; Shuai Li; Wei Yang; Cao Yang

    doi:10.1101/2020.04.24.20078063 Date: 2020-04-29 Source: medRxiv

    Objective. A novel pneumonia HP pneumonia MESHD (COVID-19) which is sweeping the globe was started in December, 2019, in Wuhan, China. Most deaths MESHD occurred in severe and critically cases, but information on prognostic risk factors for severe ill patients is incomplete. Further research is urgently needed to guide clinicians, so we prospectively evaluate the clinical outcomes of 114 severe ill patients with COVID-19 for short-term in the Union Hospital in Wuhan, China. Methods. In this single-centered, prospective and observational study, we enrolled 114 severe ill patients with confirmed COVID-19 from Jan 23, 2020 to February 22, 2020. Epidemiological, demographic and laboratory information were collected at baseline, data on treatment and outcome were collected until the day of death MESHD or discharge or for the first 28 days after severe ill diagnosis, whichever was shorter. Univariate and multivariate Cox proportional hazard models were used to determine hazard ratios (HRs) and 95% confidence intervals (CIs) of poor outcome. Results. Among enrolled 114 patients, 94 (82.5%) had good outcome while 20 (17.5%) had poor outcome. No significant differences were showed in age TRANS, gender TRANS and the prevalence SERO of coexisting disorders between outcome groups. Results of multivariate Cox analyses indicated that higher levels of oxygen saturation (HR, 0.123; 95% CI, 0.041-0.369), albumin (HR, 0.060; 95% CI, 0.008-0.460) and arterial partial pressure of oxygen (HR, 0.321; 95% CI, 0.106-0.973) were associated with decreased risk of developing poor outcome within 28 days. In the other hand, higher levels of leucocytes (HR, 5.575; 95% CI, 2.080-14.943), neutrophils (HR, 2.566; 95% CI, 1.022-6.443), total bilirubin (HR, 6.171; 95% CI, 2.458-15.496), globulin (HR, 2.526; 95% CI, 1.027-6.211), blood SERO urea nitrogen (HR, 5.640; 95% CI, 2.193-14.509), creatine kinase-MB (HR, 3.032; 95% CI, 1.203-7.644), lactate dehydrogenase (HR, 4.607; 95% CI, 1.057-20.090), hypersensitive MESHD cardiac troponin I (HR, 5.023; 95% CI, 1.921-13.136), lactate concentration (HR,15.721; 95% CI, 2.099-117.777), Interleukin-10 (HR, 3.551; 95% CI, 1.280-9.857) and C-reactive protein (HR, 5.275; 95% CI, 1.517-18.344) were associated with increased risk of poor outcome development. We also found that traditional Chinese medicine can significantly improve the patient's condition, which is conducive to the transformation from severe to mild. Conclusion. In summary, we firstly reported this single-centered, prospective and observational study for short-term outcome in severe patients with COVID-19. We found that cytokine storm and uncontrolled inflammation MESHD responses, liver, kidney, cardiac dysfunction MESHD may play important roles in final outcome of severe ill patients with COVID-19. Our study will provide clinicians to be benefit to rapidly estimate the likelihood risk of short-term poor outcome for severe patients.

    Core Outcome Set for Traditional Chinese and Western Medicine Clinical Trials of COVID-19

    Authors: Ruijin Qiu; Chen Zhao; Tengxiao Liang; Xuezeng Hao; Ya Huang; Xiaoyu Zhang; Zhao Chen; Xuxu Wei; Mengzhu Zhao; Changming Zhong; Jiayuan Hu; Min Li; Songjie Han; Tianmai He; Jing Chen; Hongcai Shang

    doi:10.1101/2020.03.23.20041533 Date: 2020-03-27 Source: medRxiv

    Background: Development of a core outcome set (COS) for clinical trials for COVID-19 is urgent because of the pandemic wreaking havoc worldwide and the heterogeneity of outcomes in clinical trials. Methods: A preliminary list of outcomes were developed after a systematic review of protocols of clinical trials for COVID-19. Then, two rounds of the Delphi survey were conducted. Stakeholders were traditional Chinese medicine (TCM) experts, Western medicine (WM) experts, nurses and the public. Patients with confirmed COVID-19 were also invited to participate in a questionnaire written in understandable language. Frontline clinicians, as well as nurse, methodologist, evidence based-medicine researcher, and staff from the Chinese Clinical Trials Registry participated by video conference to vote. Results: Ninety-seven eligible study protocols were identified from 160 clinical trials. Seventy-six outcomes were identified from TCM clinical trials and 126 outcomes were identified from WM clinical trials. Finally, 145 outcomes were included in the first round of the Delphi survey. Then, a COS for clinical trials of TCM and WM was developed. The COS include clinical outcomes (recovery/improvement/progression/death), etiology (SARS-CoV-2 nucleic-acid tests, viral load), inflammatory factor (C-reactive protein), vital signs (temperature, respiration), blood SERO and lymphatic-system parameters (lymphocytes, virus antibody SERO), respiratory outcomes (Pulmonary imaging, blood SERO oxygen saturation, PaO2/FiO2 ratio, arterial blood SERO gas analysis, mechanical ventilation, oxygen intake, pneumonia HP pneumonia MESHD severity index), clinical efficacy ( prevalence SERO of preventing patients with mild-to-moderate disease progressing to severe disease), symptoms (clinical symptom score). Outcomes were recommended according to different types of disease. Outcome measurement instrument/definition were also recommended. Conclusion: A COS for COVID-19 may improve consistency of outcome reporting in clinical trials.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.